Nurse Practitioner · Las Vegas, NV
NPI
1093340770
Since 2020
Specialty
Nurse Practitioner
Code 363L00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
3483 S Eastern Ave
Las Vegas, NV, 89169
Phone (702) 309-2311
Groups this clinician bills Medicare through
Medicare paid, 2024
$8,227
153 services
Medicare patients, 2024
65
Average age 71
Drug cost, 2024
$1.1M
661 prescriptions
Company payments, 2025
$2,156
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Aya Werra was code 99213 (office e&m - established), 126 times for 59 patients. In total Aya Werra billed 153 services in 4 codes, and Medicare paid $8,227.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 126 | 59 | $48.10 | $6,061 |
| 99214 Office E&M - Established | Office | 24 | 20 | $80.00 | $1,920 |
By year: 2022 $16K for 212 services; 2023 $12K for 203 services; 2024 $8,227 for 153 services.
Medicare prescription drug claims, 2024
In 2024, the drug Aya Werra prescribed most often to Medicare patients was Fosfomycin Tromethamine, with 120 prescriptions and refills. In total Aya Werra wrote 661 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Fosfomycin Tromethamine Generic | 120 | 127 | 31 | $30K |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 63 | 63 | Under 11 | $249K |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 50 | 62 | 28 | $735 |
| Doxycycline Hyclate Generic | 46 | 52 | 29 | $413 |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 38 | 38 | Under 11 | $146K |
| Dovato Dolutegravir Sodium/Lamivudine | 31 | 31 | Under 11 | $93K |
| Ethambutol Hcl Generic | 25 | 31 | Under 11 | $919 |
| Cefdinir Generic | 20 | 22 | 12 | $537 |
| Cabenuva Cabotegravir/Rilpivirine | 20 | 36 | Under 11 | $143K |
| Cephalexin Generic | 20 | 23 | 13 | $100 |
| Levofloxacin Generic | 19 | 19 | 16 | $153 |
| Rifampin Generic | 18 | 25 | Under 11 | $602 |
| Ciprofloxacin Hcl Generic | 17 | 17 | Under 11 | $85.81 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 16 | 16 | Under 11 | $22.74 |
| Isoniazid Generic | 15 | 26 | Under 11 | $82.93 |
Brand drugs: 246 claims; generic drugs: 415 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Aya Werra $2,156 ($2,156 in general payments such as food, travel and fees) from 14 companies. The largest payer was ViiV Healthcare Company with $915.
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company GSK | 39 | $915 |
| Abbvie Inc. ABBV | 10 | $241 |
| Merck Sharp & Dohme LLC MRK | 7 | $201 |
| Gilead Sciences, Inc. GILD | 14 | $189 |
| Shionogi Inc 4507.T | 10 | $177 |
| Paratek Pharmaceuticals, Inc. | 6 | $109 |
| La Jolla Pharmaceutical Company | 3 | $59.97 |
| Ferring Pharmaceuticals Inc. | 2 | $58.17 |
| Melinta Therapeutics, LLC | 2 | $48.1 |
| Aimmune Therapeutics, Inc. | 2 | $41.94 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.